>
Switch to:

PTC Therapeutics Gross Margin %

: 93.19% (As of Mar. 2022)
View and export this data going back to 2013. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. PTC Therapeutics's Gross Profit for the three months ended in Mar. 2022 was $138.6 Mil. PTC Therapeutics's Revenue for the three months ended in Mar. 2022 was $148.7 Mil. Therefore, PTC Therapeutics's Gross Margin % for the quarter that ended in Mar. 2022 was 93.19%.


The historical rank and industry rank for PTC Therapeutics's Gross Margin % or its related term are showing as below:

PTCT' s Gross Margin % Range Over the Past 10 Years
Min: 94   Med: 95.21   Max: 97.65
Current: 94.14


During the past 11 years, the highest Gross Margin % of PTC Therapeutics was 97.65%. The lowest was 94.00%. And the median was 95.21%.

PTCT's Gross Margin % is ranked better than
89.52% of 725 companies
in the Biotechnology industry
Industry Median: 61.57 vs PTCT: 94.14

PTC Therapeutics had a gross margin of 93.19% for the quarter that ended in Mar. 2022 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for PTC Therapeutics was 0.00% per year.


PTC Therapeutics Gross Margin % Historical Data

The historical data trend for PTC Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.65 95.21 96.05 95.03 94.00

PTC Therapeutics Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.28 93.69 95.29 94.36 93.19

Competitive Comparison

For the Biotechnology subindustry, PTC Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

PTC Therapeutics Gross Margin % Distribution

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's Gross Margin % falls into.



PTC Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

PTC Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2021 is calculated as

Gross Margin % (A: Dec. 2021 )=Gross Profit (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=506.3 / 538.593
=(Revenue - Cost of Goods Sold) / Revenue
=(538.593 - 32.328) / 538.593
=94.00 %

PTC Therapeutics's Gross Margin for the quarter that ended in Mar. 2022 is calculated as


Gross Margin % (Q: Mar. 2022 )=Gross Profit (Q: Mar. 2022 ) / Revenue (Q: Mar. 2022 )
=138.6 / 148.735
=(Revenue - Cost of Goods Sold) / Revenue
=(148.735 - 10.135) / 148.735
=93.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


PTC Therapeutics  (NAS:PTCT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

PTC Therapeutics had a gross margin of 93.19% for the quarter that ended in Mar. 2022 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


PTC Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics Business Description

PTC Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
Southwell David P director C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421
Jacobson Allan Steven director PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Peltz Stuart Walter director, officer: Chief Executive Officer PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Utter Christine Marie officer: SVP, Finance & CAO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Boulding Mark Elliott officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Hill Emily Luisa officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Svoronos Dawn director C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105
Pauwels Eric officer: Chief Business Officer 550 HILLS DRIVE BEDMINSTER NJ 07921
Klein Matthew B. officer: Chief Development Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Schmertzler Michael director 1300 VALLEY ROAD NEW CANAAN CT 06840
Souza Marcio officer: Chief Operating Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Almstead Neil Gregory officer: Chief Technical Ops Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Reeve Emma director C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451
Steele Glenn Jr Md Phd director 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232
Zeldis Jerome B director 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258

PTC Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)